Loading
Life sciences · Journal article
Pathogens · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Third-generation cephalosporin (3GC) resistance threatens empirical therapy in vulnerable critically ill patients. We conducted a decade-long single-center retrospective study of 3528 Gram-negative isolates from 1946 adult and pediatric oncology intensive care unit (ICU) patients between 2015 and 2024 at King Hussein Cancer Center. This study aims to characterize 3GS resistance in oncology ICU patients. The 3GC resistance was 59.2% among Enterobacterales and other fermenting organisms (evaluated against the full three-agent panel) and 67.2%among non-fermenters (Pseudomonas aeruginosa, Acinetobacter spp., Stenotrophomonas maltophilia; evaluated against a narrower, organism-appropriate agent subset); these two estimates are not directly comparable given the differing susceptibility panels tested. Resistance was highest among the Acinetobacter calcoaceticus-baumannii complex (96.9%), followed by Escherichia coli (70.5%), Enterobacter cloacae (65.5%), and Klebsiella pneumoniae (59.6%). In unadjusted patient-level analyses, resistance was significantly higher among patients with hematological malignancy than solid tumors (73.1% vs. 57.8%; OR 1.98, 95% CI 1.59–2.48; p < 0.001) and among pediatric versus adult ICU isolates (70.8% vs. 60.9%; OR 1.55, 95% CI 1.11–2.18; p = 0.010). Seven-day mortality did not differ by resistance status (44.1% vs. 41.6%; unadjusted OR 1.11, 95% CI 0.92–1.33). The 3GC resistance varies by organism, malignancy type and ICU population in unadjusted analyses, supporting population-specific antibiograms and stronger stewardship.